Roche's Challenge With Herceptin Gastric Cancer Claim Will Be Companion Dx Use
This article was originally published in The Pink Sheet Daily
Executive Summary
As with Herceptin in breast cancer, the drug is approved simultaneously with a companion diagnostic to measure HER2 levels in gastric cancer patients, but the use of the test is different.
You may also be interested in...
Singapore's ASLAN Licenses Gastric Cancer Compound From Array; Will Bring To POC And Find Partner
Singapore's ASLAN Pharmaceuticals Pte Ltd. has inked a licensing deal with Colorado-based Array BioPharma Inc. to develop Array's oral HER2/EGFR inhibitor ARRY-543, currently entering Phase II for solid tumors
Array BioPharma Licenses Gastric Cancer Compound To Singapore's ASLAN; ASLAN Will Bring To POC And Find Partner
Partnership enables Array to focus its resources on two compounds that are furthest in development and gain expertise in the Asian market.
Array BioPharma Licenses Gastric Cancer Compound To Singapore's ASLAN; ASLAN Will Bring To POC And Find Partner
Partnership enables Array to focus its resources on two compounds that are furthest in development and gain expertise in the Asian market.